Literature DB >> 32696288

The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic.

Mahsa Pourhamzeh1,2,3, Mohammad Taghi Joghataei4,5, Soraya Mehrabi6, Reza Ahadi1, Seyed Mohammad Massood Hojjati7, Nasrin Fazli2, Seyed Massood Nabavi2, Hossein Pakdaman8, Koorosh Shahpasand9.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder, in which amyloid precursor protein (APP) misprocessing and tau protein hyperphosphorylation are well-established pathogenic cascades. Despite extensive considerations, the central mediator of neuronal cell death upon AD remains under debate. Therefore, we examined the direct interplay between tauopathy and amyloidopathy processes. We employed primary culture neurons and examined pathogenic P-tau and Aβ oligomers upon hypoxia treatment by immunofluorescence and immunoblotting. We observed both tauopathy and amyloidopathy processes upon the hypoxia condition. We also applied Aβ1-42 or P-tau onto primary cultured neurons. We overexpressed P-tau in SH-SY5Y cells and found Aβ accumulation. Furthermore, adult male rats received Aβ1-42 or pathogenic P-tau in the dorsal hippocampus and were examined for 8 weeks. Learning and memory performance, as well as anxiety behaviors, were assessed by Morris water maze and elevated plus-maze tests. Both Aβ1-42 and pathogenic P-tau significantly induced learning and memory deficits and enhanced anxiety behavior after treatment 2 weeks. Aβ administration induced robust tauopathy distribution in the cortex, striatum, and corpus callosum as well as CA1. On the other hand, P-tau treatment developed Aβ oligomers in the cortex and CA1 only. Our findings indicate that Aβ1-42 and pathogenic P-tau may induce each other and cause almost identical neurotoxicity in a time-dependent manner, while tauopathy seems to be more distributable than amyloidopathy.

Entities:  

Keywords:  Alzheimer’s disease; Oxidative stress; P-tau; β-Amyloid

Mesh:

Substances:

Year:  2020        PMID: 32696288     DOI: 10.1007/s10571-020-00906-2

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  61 in total

1.  The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes.

Authors:  Juan C Chavez; Oxana Baranova; Janice Lin; Paola Pichiule
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

2.  Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease.

Authors:  D Boyd-Kimball; R Sultana; H Fai Poon; B C Lynn; F Casamenti; G Pepeu; J B Klein; D A Butterfield
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.

Authors:  Diana L Castillo-Carranza; Marcos J Guerrero-Muñoz; Urmi Sengupta; Caterina Hernandez; Alan D T Barrett; Kelly Dineley; Rakez Kayed
Journal:  J Neurosci       Date:  2015-03-25       Impact factor: 6.167

Review 4.  Stress as risk factor for Alzheimer's disease.

Authors:  Alessandra Caruso; Ferdinando Nicoletti; Dalila Mango; Amira Saidi; Rosamaria Orlando; Sergio Scaccianoce
Journal:  Pharmacol Res       Date:  2018-04-22       Impact factor: 7.658

5.  Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease.

Authors:  Mubeen Ahmad Ansari; Hafiz Mohammad Abdul; Gururaj Joshi; Wycliffe O Opii; D Allan Butterfield
Journal:  J Nutr Biochem       Date:  2008-07-07       Impact factor: 6.048

6.  Metabolic, enzymatic and gene involvement in cerebral glucose dysmetabolism after traumatic brain injury.

Authors:  Angela Maria Amorini; Giacomo Lazzarino; Valentina Di Pietro; Stefano Signoretti; Giuseppe Lazzarino; Antonio Belli; Barbara Tavazzi
Journal:  Biochim Biophys Acta       Date:  2016-02-01

7.  Soluble aβ promotes wild-type tau pathology in vivo.

Authors:  Meredith A Chabrier; Mathew Blurton-Jones; Andranik A Agazaryan; Joy L Nerhus; Hilda Martinez-Coria; Frank M LaFerla
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

8.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Authors:  Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal:  Sci Transl Med       Date:  2016-05-11       Impact factor: 17.956

9.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

10.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity.

Authors:  Zeshan Ahmed; Jane Cooper; Tracey K Murray; Katya Garn; Emily McNaughton; Hannah Clarke; Samira Parhizkar; Mark A Ward; Annalisa Cavallini; Samuel Jackson; Suchira Bose; Florence Clavaguera; Markus Tolnay; Isabelle Lavenir; Michel Goedert; Michael L Hutton; Michael J O'Neill
Journal:  Acta Neuropathol       Date:  2014-02-16       Impact factor: 17.088

View more
  2 in total

Review 1.  Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.

Authors:  Isabelle Aillaud; Susanne Aileen Funke
Journal:  Cell Mol Neurobiol       Date:  2022-05-21       Impact factor: 5.046

Review 2.  Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations.

Authors:  Yuto Uchida; Hirohito Kan; Keita Sakurai; Kenichi Oishi; Noriyuki Matsukawa
Journal:  Front Neurosci       Date:  2022-08-05       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.